RVAC Medicines

Recent Finacing

Series B

Recent Raise

$140M

RVAC Medicines is a Singapore‑headquartered mRNA platform company developing vaccines and therapeutics for infectious, autoimmune, and cancer indications, leveraging Acuitas LNP delivery and R&D sites in Boston and Shanghai.

Founded 2021

Central Region, Singapore

51-100

Private

rvacmed.com

Highlights

Focus Areas

Biotechnology

Medical

Product Research

Recent Investors

Financials

$140M

Total Raised

1

Funding round

4

Investors

Team

Upgrade to view the team

See the team members at RVAC Medicines.